5-HT3 antagonist 5

  Cat. No.:  DC60308   Featured
Chemical Structure
901599-43-7
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
5-HT3 antagonist 5 is a quinoxalin-2-carboxamide compound, a 5-HT3 receptor antagonist. 5-HT3 antagonist 5 exerts antagonism on 5-HT3 agonist and 2-methyl-5-HT, and shows anti-depressant effect in mice[1].
Cas No.: 901599-43-7
Chemical Name: 5-HT3 antagonist 5
Synonyms: 2-Quinoxalinecarboxamide, N-(4-methoxyphenyl)-;WAY-327157;N-(4-Methoxyphenyl)-2-quinoxalinecarboxamide (ACI);5-HT3 antagonist 5
SMILES: O=C(C1C=NC2C(=CC=CC=2)N=1)NC1C=CC(OC)=CC=1
Formula: C16H13N3O2
M.Wt: 279.293323278427
Purity: >98%
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Description: 5-HT3 antagonist 5 is a quinoxalin-2-carboxamide compound, a 5-HT3 receptor antagonist. 5-HT3 antagonist 5 exerts antagonism on 5-HT3 agonist and 2-methyl-5-HT, and shows anti-depressant effect in mice[1].
Target: 5-HT3 Receptor
In Vivo: 5-HT3 antagonist 5 (compound 4c) (1 mg/kg; i.p.; single dose) decreases the duration of immobility and shows anti-depressant effect in FST mice[1]. Animal Model: Swiss albino mice (23 ± 2 g)[1] Dosage: 1 mg/kg Administration: Intraperitoneal injection; single dose; locomotor scores tested 10 min after administration Result: Reduced the duration of immobility as compared to the vehicle-treated (control) group. Showed no effect on the locomotion of mice as observed in spontaneous locomotor activity.
In Vitro: 5-HT3 antagonist 5 (compound 4c) exhibits 5-HT3 receptor antagonisms in longitudinal muscle myenteric plexus preparation from guinea pig ileum against 5-HT3 agonist, 2-methyl-5-HT, with pA2 value of 5[1].
References: [1]. Mahesh R, et al. Design, synthesis and structure-activity relationship of novel quinoxalin-2-carboxamides as 5-HT3 receptor antagonists for the management of depression. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6773-6.
MSDS
COA
LOT NO. DOWNLOAD
2018-0101
Cat. No. Product name Field of application
DC33635 DODAP DODAP, also known as 1,2-Dioleoyl-3-dimethylammonium-propane, is a cationic lipid. It has been used as a component in liposomes that can be used to encapsulate siRNA, immunostimulatory oligodeoxynucleotides, antisense oligonucleotides, or chemotherapeutic agents for in vitro and in vivo delivery.
DC58047 DSPE-PEG 2000 PEG2000-DSPE is used for creating micelles that are able to carry drugs with low solubility.
DC31000 LP-01 LP-01 is an ionizable cationic amino lipid (pKa = ~6.1). It has been used in the generation of lipid nanoparticles (LNPs). LNPs containing LP-01 and encapsulating both Cas9 mRNA and modified single-guide RNA (sgRNA) for the transport protein transthyretin (Ttr) induce gene editing in liver cells in mice in a dose-dependent manner resulting in reduced serum Ttr levels for at least 12 months.
DC66546 R-Sirpiglenastat R-Sirpiglenastat is the R- isomer of Sirpiglenastat(DRP-104).Sirpiglenastat (DRP104) is a broad acting glutamine antagonist. Sirpiglenastat has anticancer effects by directly targeting tumor metabolism and simultaneously inducing a potent antitumor immune response.
DC60597 AZD0780 AZD0780 is the first oral small molecule PCSK9 inhibitor for the treatment of hypercholesterolemia.
DC66114 FAPI-46 FAPI46 is a quinoline-based fibroblast activation protein (FAP)-targeted radiotracer. FAPI-46 has higher tumor uptake and prolonged tumor accumulation. FAPI 46 can be used for tumor imaging of a multitude of different cancers.
DC60580 Endosidin5(ES5) Endosidine 5 (ES5), is one of the most potent small molecules interferes with recycling endosomes through Annexin A6, thereby promoting the release and expression of mRNA into the cytoplasm. The delivered mRNAs is greatly enhanced via inhibition of endocytic recycling in cells and in live mice. NAV2729 (NAV) and endosidin 5 (ES5), resulted in significant enhancement (1.5–2 folds) of LNP-mediated delivery of Fluc mRNAs. Incubation of NAV and ES5 together caused modest further increases in Fluc expression in comparison to the sole application of either compound.
DC90056 PLX-5622 HCl form (water solubility form) PLX5622 is the HCl salt form of PLX-5622, which has better water solubility.PLX-5622 is a highly selective brain-penetrant CSF1R inhibitor (IC50=0.016 µM; Ki=5.9 nM) allowing for extended and specific microglial elimination, preceding and during pathology development.
DC60559 PT-179 PT-179 is a new orthogonal immunomodulatory drug (IMiD) derivative that binds CRBN but does not induce degradation of off-target proteins. PT-179 potently degrades proteins fused to SD40 at either the N or C terminus.
DC65841 MC1 MC1 is a selective and potent inhibitor for COX-2, and [11C]MC1 detected COX-2 in nonhuman primates after intracerebral injection of an inflammogen.
X